We provide solutions for critical key factors of immunoassay development in order to…
… optimize specificity, sensitivity, stability and cross reactivity.
… improve test performance and result reliability.
… save time and costs.
Nanoconjugates
With our proprietary NanoConjugates, VHH antibodies enter the field of serological infection diagnosis.
Their small size and binding characteristics come along with convincing benefits compared to conventional antibody conjugates:
Maximal reproducibility enabled by clonal synthesis in E. coli:
Neglegtable lot-to-lot variability and therefore reduction of time usually required for internal controls and adjustments.
Flexibility regarding the reporter system:
Due to our modular system, NanoConjugates can easily be combined with any reporter of choice.
Reliable Antigen binding properties:
Our acridinylated NanoConjugates are labelled in a targeted manner. Antigen binding sites stay free.
Enhanced stability:
Easier storage and higher robustness during processing.
Steric advantages regarding the binding of antigen epitopes and therefore larger detection spectrum.
Due to their small size (~15 kDa), VHH antibodies reach epitopes which are hardly accessible for full size antibodies (~150 kDa).
Better or at least equal performance in critical test parameters:
Specificity, sensitivity, signal intensity, cross reactivity.
Avoid unexpected cross reactivities caused by animal derived supplements.
Animal free production:
Replace animal derived products, accomodate institutional animal wellfare guidelines and avoid complicated international transportation regulations.